DR. PENG(SH:600804)2025-01-22 12:50Financial Performance Expectations - The company expects a total profit of approximately -69.7 million yuan for the year 2024, with a net profit attributable to shareholders of approximately -77.5 million yuan, and a net profit of approximately -73.6 million yuan after deducting non-recurring gains and losses [3]. - The estimated operating revenue for 2024 is approximately 188.7 million yuan, with approximately 185.8 million yuan after excluding unrelated business income and income without commercial substance [5]. - The company's net assets attributable to shareholders are expected to be approximately 19 million yuan by the end of 2024 [5]. - In the same period last year, the total profit was -14.72 million yuan, and the net profit attributable to shareholders was -9.32 million yuan [6]. - The operating revenue for the same period last year was 260.6 million yuan, with 243.67 million yuan after excluding unrelated business income [6]. Revenue Decline Factors - The decline in revenue is attributed to intensified market competition and a decrease in new customer acquisition, particularly in key regions like Beijing, Shanghai, and Shenzhen [7]. Impairment and Non-Operating Losses - The company anticipates impairment losses of approximately 18.3 million yuan, primarily due to asset impairment and credit impairment losses [7]. - Non-operating gains and losses for the period are estimated at approximately -3.9 million yuan, mainly from pending litigation, fines, and government subsidies [7]. Audit and Compliance Issues - The company’s stock has been placed under delisting risk warning due to the inability of the auditing firm to express an opinion on the 2023 annual audit report [9]. - The financial data provided is preliminary and has not been audited, with the final figures to be disclosed in the audited annual report for 2024 [10].